Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis
| Autor: | Ting Yuan, Xin Wang, Qing-Min Yao, Feng Zhang, Yan-Xia Liu, Xiao-juan Zhu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Male lcsh:Medicine Toxicology Pathology and Laboratory Medicine Hematologic Cancers and Related Disorders Bortezomib Database and Informatics Methods White Blood Cells 0302 clinical medicine Mathematical and Statistical Techniques Animal Cells immune system diseases hemic and lymphatic diseases Indolent Non-Hodgkin Lymphoma Medicine and Health Sciences Database Searching lcsh:Science Clinical Trials as Topic Multidisciplinary Lymphoma Non-Hodgkin Nausea Hematology Middle Aged Treatment Outcome Research Design 030220 oncology & carcinogenesis Physical Sciences Lymphomas Female medicine.symptom Cellular Types Statistics (Mathematics) medicine.drug Research Article Diarrhea medicine.medical_specialty Neutropenia Clinical Research Design Immune Cells Immunology Antineoplastic Agents Gastroenterology and Hepatology Research and Analysis Methods Drug Administration Schedule 03 medical and health sciences Signs and Symptoms Diagnostic Medicine Internal medicine medicine Humans Statistical Methods Adverse effect Survival analysis Aged Blood Cells Toxicity business.industry lcsh:R Cancers and Neoplasms Biology and Life Sciences Cell Biology medicine.disease Survival Analysis Lymphoma Clinical trial lcsh:Q Adverse Events business Mathematics 030215 immunology Meta-Analysis |
| Zdroj: | PLoS ONE, Vol 12, Iss 5, p e0177950 (2017) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Background Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. Methods We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate. The secondary outcomes were the proportions of patients in each group experiencing the adverse events including the neutropathy, fatigue, diarrhea, nausea and neutropenia. Findings After final screening, six trials were considered eligible for analysis. The results showed that the overall response rate of biweekly schedule was higher than that of weekly schedule in indolent lymphoma (OR 1.691;95%CI 1.02-2.80). Furthermore, there were no significant differences between the two schedules of bortezomib for the main adverse events. Interpretation The biweekly schedule of bortezomib was more effective than the weekly schedule in indolent lymphoma, with similar proportion of toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|